MX2015012441A - Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina. - Google Patents

Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina.

Info

Publication number
MX2015012441A
MX2015012441A MX2015012441A MX2015012441A MX2015012441A MX 2015012441 A MX2015012441 A MX 2015012441A MX 2015012441 A MX2015012441 A MX 2015012441A MX 2015012441 A MX2015012441 A MX 2015012441A MX 2015012441 A MX2015012441 A MX 2015012441A
Authority
MX
Mexico
Prior art keywords
heparin
monoclonal antibodies
antibodies against
complexed
antibodies
Prior art date
Application number
MX2015012441A
Other languages
English (en)
Spanish (es)
Inventor
Hermiston Terry
E Murphy John
Jin Ye
Myles Timothy
Dittmer Frank
Strerath Michael
Gritzan Uwe
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015012441(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2015012441A publication Critical patent/MX2015012441A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015012441A 2013-03-14 2014-03-14 Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina. MX2015012441A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784590P 2013-03-14 2013-03-14
PCT/US2014/029541 WO2014153195A1 (en) 2013-03-14 2014-03-14 Monoclonal antibodies against antithrombin beta complexed with heparin

Publications (1)

Publication Number Publication Date
MX2015012441A true MX2015012441A (es) 2016-08-08

Family

ID=50680168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012441A MX2015012441A (es) 2013-03-14 2014-03-14 Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina.

Country Status (18)

Country Link
US (4) US9908942B2 (cg-RX-API-DMAC7.html)
EP (1) EP2970500A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016519081A (cg-RX-API-DMAC7.html)
KR (1) KR20150127202A (cg-RX-API-DMAC7.html)
CN (1) CN105229033B (cg-RX-API-DMAC7.html)
AR (1) AR095499A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014236198A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015021399A2 (cg-RX-API-DMAC7.html)
CA (1) CA2916421A1 (cg-RX-API-DMAC7.html)
HK (1) HK1215261A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015012441A (cg-RX-API-DMAC7.html)
PE (1) PE20160533A1 (cg-RX-API-DMAC7.html)
RU (1) RU2015143696A (cg-RX-API-DMAC7.html)
SG (1) SG11201506886TA (cg-RX-API-DMAC7.html)
TW (1) TW201529602A (cg-RX-API-DMAC7.html)
UY (1) UY35457A (cg-RX-API-DMAC7.html)
WO (1) WO2014153195A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201507628B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35457A (es) 2013-03-14 2014-10-31 Bayer Healthcare Llc ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA ß
EP3146759B1 (en) * 2014-05-19 2021-04-07 Nokia Solutions and Networks Oy Re-establishment procedure in dual connectivity networks
MY193078A (en) 2015-06-24 2022-09-26 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
CN108137697A (zh) 2015-10-02 2018-06-08 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP2019516347A (ja) * 2016-03-18 2019-06-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 抗アンチトロンビン単一ドメイン抗体及びそれを含むポリペプチド

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5578253A (en) 1978-12-11 1980-06-12 Teikoku Hormone Mfg Co Ltd Immune measurement of hito antithrombin 3
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
BE896543A (fr) 1983-04-22 1983-08-16 Wallone Region Ensembles d'anticorps monoclonaux deriges contre les proteines humaines impliquees dans la coagulation et la fibrinolyse du sang
JPH0644876B2 (ja) 1985-12-13 1994-06-15 株式会社ヤトロン 抗トロンビン・アンチトロンビン３複合体モノクローナル抗体、及びその製造方法、並びにそれを用いるトロンビン・アンチトロンビン３複合体の免疫定量法、及びそれを用いるトロンビン・アンチトロンビン３複合体の精製方法
JPH0266458A (ja) 1988-09-01 1990-03-06 Takara Shuzo Co Ltd ビトロネクチン及びビトロネクチン‐トロンビン‐アンチトロンビン３複合体の測定方法
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU628960B2 (en) 1989-04-07 1992-09-24 Teijin Limited Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
JPH0694713A (ja) 1991-07-31 1994-04-08 Masashi Funayama アンチトロンビンｉｉｉ活性の測定方法とそれを用いたアンチトロンビンｉｉｉ活性の測定キット
JPH07238099A (ja) 1994-02-25 1995-09-12 Dai Ichi Pure Chem Co Ltd モノクローナル抗体及びこれを用いる免疫学的測定法
FR2718849B1 (fr) 1994-04-14 1996-06-14 Pasteur Sanofi Diagnostics Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention.
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
JP3841364B2 (ja) 1994-10-18 2006-11-01 株式会社三菱化学ヤトロン 抗ヒトビトロネクチン・トロンビン・アンチトロンビンｉｉｉ 複合体モノクローナル抗体、ハイブリドーマ及び免疫学的測定方法
KR20000015893A (ko) 1996-05-22 2000-03-15 댄 마이클 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도
JP2000511050A (ja) 1996-05-31 2000-08-29 メディジーン・アクチェンゲゼルシャフト 機能性分子表面の生成、スクリーニング、および展開のための新規の合成タンパク質の構造の鋳型
ES2299425T3 (es) 1999-05-13 2008-06-01 Gtc Biotherapeutics, Inc. Antitrombina iii producida geneticamente y formas mutantes de la misma.
JP2001321167A (ja) 2000-05-10 2001-11-20 Cosmo Research Inst モノクローナル抗体
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
JP2002316999A (ja) 2001-04-17 2002-10-31 Dai Ichi Pure Chem Co Ltd モノクローナル抗体
US20090226429A1 (en) 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
EP1499353A4 (en) 2002-04-15 2006-04-05 Human Genome Sciences Inc SPECIFIC TO TL5 BINDING ANTIBODIES
US7482139B2 (en) 2002-05-31 2009-01-27 University Of Utah Research Foundation Variants of antithrombin III
EP1382615A1 (en) 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
RU2262109C2 (ru) 2002-12-30 2005-10-10 Институт биохимической физики им. Н.М. Эмануэля Российской академии наук Способ определения концентрации антитромбина iii в плазме крови
WO2004083249A2 (en) 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
EP1633316A4 (en) 2003-05-06 2008-04-02 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
GB2404981A (en) 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7271245B2 (en) 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
AU2006210660B2 (en) 2005-02-01 2011-12-01 Morphosys Ag Libraries and methods for isolating antibodies
CA2694047C (en) 2007-07-20 2018-01-30 Universite Paris-Sud Xi Use of mutated antithrombins for treating or preventing coagulation disorders
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
NZ593837A (en) 2007-11-29 2013-01-25 Grifols Therapeutics Inc Recombinantly modified plasmin
ES2346618B1 (es) 2008-08-14 2011-08-03 Universidad De Murcia Anticuerpo monoclonal anti antitrombina citrulinada humana y sus usos.
NO330078B1 (no) 2008-09-22 2011-02-14 Optipro As Fremgangsmåte og apparat for å overvåke slitasje i sikteduker
WO2010047830A2 (en) 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
EP3401333B1 (en) 2010-09-09 2021-05-19 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
US20140356377A1 (en) 2011-08-25 2014-12-04 Umc Utrecht Holding B.V. Compounds for use in boosting coagulation
CN103930595A (zh) 2011-11-11 2014-07-16 Sio2医药产品公司 用于药物包装的钝化、pH保护性或润滑性涂层、涂布方法以及设备
UY35457A (es) * 2013-03-14 2014-10-31 Bayer Healthcare Llc ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA ß
JP6094713B1 (ja) 2016-06-30 2017-03-15 富士ゼロックス株式会社 定着部材、定着装置、及び画像形成装置

Also Published As

Publication number Publication date
TW201529602A (zh) 2015-08-01
HK1215261A1 (zh) 2016-08-19
BR112015021399A2 (pt) 2017-07-18
RU2015143696A (ru) 2017-04-19
ZA201507628B (en) 2017-11-29
US9908942B2 (en) 2018-03-06
US10144784B2 (en) 2018-12-04
US9593166B2 (en) 2017-03-14
PE20160533A1 (es) 2016-06-09
CN105229033A (zh) 2016-01-06
US20160024222A1 (en) 2016-01-28
CN105229033B (zh) 2019-04-23
US20140271660A1 (en) 2014-09-18
AR095499A1 (es) 2015-10-21
US20140271661A1 (en) 2014-09-18
WO2014153195A1 (en) 2014-09-25
AU2014236198A1 (en) 2015-10-15
CA2916421A1 (en) 2014-09-25
EP2970500A1 (en) 2016-01-20
US20180244799A1 (en) 2018-08-30
JP2016519081A (ja) 2016-06-30
KR20150127202A (ko) 2015-11-16
UY35457A (es) 2014-10-31
SG11201506886TA (en) 2015-09-29

Similar Documents

Publication Publication Date Title
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12016500943A1 (en) Aplnr modulatros and uses thereof
MX382398B (es) Proteinas de union a antigeno st2.
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
WO2014164959A3 (en) Anti-il-33 antibodies and uses thereof
MX369148B (es) Agentes de unión kir3dl2.
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
EA201890143A3 (ru) Антитела против pdgfr-бета и их применения
MX2015012441A (es) Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina.
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
EA201290589A1 (ru) Cd127-связывающие белки
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
WO2014194274A3 (en) Oncostatin m receptor antigen binding proteins
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
BR112015012414A2 (pt) anticorpos monoclonais contra proteína c ativada (apc)
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
WO2014143739A3 (en) Anti-alpha v beta 6 antibodies and uses thereof
WO2013149219A3 (en) Fully human antibodies that bind to vegfr2
UA112521C2 (uk) Антитіло проти gdf8 людини
WO2014144616A3 (en) Anti-alpha v beta 5 antibodies and uses thereof
EA202090128A3 (ru) Антитела против антигена 2 дендритных клеток крови и их применение